Torno Capital LLC Purchases Shares of 20,000 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Torno Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $794,000. Centessa Pharmaceuticals comprises about 0.1% of Torno Capital LLC’s investment portfolio, making the stock its 18th biggest holding.

Several other institutional investors have also recently made changes to their positions in the business. TD Waterhouse Canada Inc. bought a new stake in Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. raised its position in Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares during the last quarter. Finally, Knott David M Jr purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth $100,000. Institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on CNTA shares. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Finally, Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $40.50 on Tuesday. The company has a 50 day simple moving average of $40.16 and a two-hundred day simple moving average of $33.89. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a market cap of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $12.74 and a 1-year high of $40.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.